Cargando…
Insurance Approval for Definitive Proton Therapy for Prostate Cancer
PURPOSE: To determine factors that influence insurance approval for definitive proton therapy (PT) for prostate cancer. MATERIALS AND METHODS: Between 2014 and 2018, 1592 insured patients with localized prostate cancer were evaluated and recommended to undergo definitive PT; 547 patients (34.4%) had...
Autores principales: | Mendenhall, William M., Brooks, Eric D., Smith, Stephanie, Morris, Christopher G., Bryant, Curtis B., Henderson, Randal H., Nichols, Romaine C., McIntyre, Kathy, Klein, Stuart L., Mendenhall, Nancy P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Particle Therapy Co-operative Group
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8768894/ https://www.ncbi.nlm.nih.gov/pubmed/35127974 http://dx.doi.org/10.14338/IJPT-21-00002.1 |
Ejemplares similares
-
Does Race Influence Health-related Quality of Life and Toxicity Following Proton Therapy for Prostate Cancer?
por: Bryant, Curtis, et al.
Publicado: (2016) -
Erectile Function, Incontinence, and Other Quality of Life Outcomes Following Proton Therapy for Prostate Cancer in Men 60 Years Old and Younger
por: Hoppe, Bradford S, et al.
Publicado: (2012) -
Postoperative or Salvage Proton Radiotherapy for Prostate Cancer After Radical Prostatectomy
por: Kharod, Shivam M., et al.
Publicado: (2021) -
Hypofractionated passively scattered proton radiotherapy for low- and intermediate-risk prostate cancer is not associated with post-treatment testosterone suppression
por: Kil, Whoon Jong, et al.
Publicado: (2013) -
Consensus Statement on Proton Therapy for Prostate Cancer
por: Bryant, Curtis M., et al.
Publicado: (2021)